このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Frailty Syndrome and Its Associated Factors Among Elderly Patients (Frailty)

2026年7月21日 更新者:Asma Ahmed Rafat Najeeb、Assiut University

Frailty Syndrome and Its Associated Factors Among Elderly Patients Attending Assiut University Hospitals

This is a cross-sectional analytical study conducted among elderly patients attending Assiut university hospital.

2.4. 2- Study Setting:The study will be conducted in Assiut University hospital, including outpatients and inpatients who fulfill inclusion criteria.

2.4. 3- Study subjects:

  • a. Inclusion criteria:
  • Age ≥ 60 years
  • Patient attending Assiut university hospital during the study period, regardless primary diagnosis.
  • Ability to provide informed consent and agreed to participate in the study.
  • Ability to communicate and answer the study questionnaire.
  • b. Exclusion criteria:
  • Age < 60 years
  • Patients admitted for elective surgical procedures or transferred from surgical wards
  • Patients with a terminal illness or those receiving palliative/end-of-life care only
  • Patients with incomplete medical records or inability to complete the assessment due to severe aphasia or critical hemodynamic instability
  • Patients with severe cognitive impairment or psychiatric disorders affecting communication.
  • Patients who refused to participate

    c. Sample Size Calculation: Based on determining the main outcome variable, the estimated minimum required sample size is 175 patients.

The sample size was calculated using Epi-Info version 7 software, based on the following assumptions:

Based on a previous study by Perez-Zepeda et al. (2023)(3), which reported a frailty prevalence of approximately 42% among hospitalized elderly patients using the Frailty Index with a deficit accumulation approach, Based on a confidence level of 90% and an absolute precision (confidence limit) of 5%.

2.4.4 Study tools:

The study will be done by using a semi structured questionnaire that will include four sections as follows:

Section I: Sociodemographic and Clinical Data Sheet:

A structured interviewer-administered data collection form will be used to record baseline sociodemographic and clinical characteristics of all enrolled patients. This will include age, sex, level of education, marital status, and place of residence. Clinical data will encompass the primary diagnosis on admission, all documented comorbidities, total number of regular medications (polypharmacy defined as the concurrent use of five or more medications), smoking history, and the number of hospital admissions within the preceding 12 months.

Section II: The 30-Item Frailty Index (FI):

Frailty will be assessed using a 30-item Frailty Index (FI) constructed in accordance with the deficit accumulation model originally proposed by Rockwood and Mitnitski. This model conceptualizes frailty as the cumulative burden of age-related health deficits across multiple physiological domains. Each deficit is coded as 0 (absent) or 1 (present); where a deficit is gradable in severity, an intermediate score of 0.5 is assigned. The FI is calculated by the following formula:

FI="Number of deficits present" /30

Participants are subsequently classified into three frailty categories according to their FI score:

FI Score Frailty Category < 0.10 Robust 0.10 - 0.24 Pre-frail

≥ 0.25 Frail

Section III. Physical examination and Anthropometric Measurements:

All participants will undergo a comprehensive physical examination including assessment of vital signs (blood pressure, pulse rate, respiratory rate, and body temperature), anthropometric measurements (weight, height and body mass index), and a systematic clinical examination relevant to the study objectives.

  • Body weight will be measured using calibrated digital scales, with the patient wearing light clothing and no shoes
  • Height will be measured using a wall-mounted stadiometer
  • BMI will be calculated accordingly Findings will be recorded in a standardized data collection sheet.

Section IV. Laboratory Investigations:

The following investigations will be collected from the routine admission workup or ordered as part of the study protocol:

  • Complete blood count (CBC) for hemoglobin and hematocrit
  • Serum albumin measured by colorimetric bromocresol green (BCG) method
  • Random blood glucose for diabetes assessment

調査の概要

状態

まだ募集していません

詳細な説明

The 30-Item Frailty Index (FI):

Frailty will be assessed using a 30-item Frailty Index (FI) constructed in accordance with the deficit accumulation model originally proposed by Rockwood and Mitnitski. This model conceptualizes frailty as the cumulative burden of age-related health deficits across multiple physiological domains. Each deficit is coded as 0 (absent) or 1 (present); where a deficit is gradable in severity, an intermediate score of 0.5 is assigned. The FI is calculated by the following formula:

FI="Number of deficits present" /30

Participants are subsequently classified into three frailty categories according to their FI score:

FI Score Frailty Category < 0.10 Robust 0.10 - 0.24 Pre-frail

≥ 0.25 Frail

The 30 deficits are distributed across six sections as follows:

Section A: Chronic Diseases (10 items) The presence of each chronic disease is confirmed through a combination of patient interview, review of medical records, and available investigation results. The ten items are: hypertension (diagnosed and/or on antihypertensive therapy); diabetes mellitus (diagnosed and/or on antidiabetic treatment); ischemic heart disease (confirmed by electrocardiography, echocardiography, or documented medical history); heart failure (diagnosed clinically and/or by echocardiographic assessment of ejection fraction); atrial fibrillation (confirmed on 12-lead ECG or Holter monitoring); prior stroke or transient ischemic attack (documented cerebrovascular event in the medical record); chronic obstructive pulmonary disease or chronic lung disease (diagnosed by spirometry or clinical assessment); chronic kidney disease (estimated glomerular filtration rate below 60 mL/min/1.73m² for more than three months); chronic liver disease (confirmed by clinical, laboratory, or imaging findings); and active or prior malignancy (confirmed by histopathological report or documented in the clinical record).

Section B: General Symptoms (5 items):

These items are assessed through a structured patient interview. They include: unintentional weight loss, defined as a loss of more than 4.5 kg or more than 5% of body weight over the preceding year; persistent fatigue, defined as self-reported fatigue present most of the time for a duration of three or more months; chronic pain, defined as pain persisting beyond three months and requiring regular analgesia or limiting daily activity; dyspnea on exertion, graded using the Modified Medical Research Council (mMRC) Dyspnea Scale with a score of 2 or above considered positive; and poor appetite, defined as self-reported reduction in food intake over the preceding month.

Section C: Basic Activities of Daily Living - ADL (5 items):

Functional status with respect to basic self-care activities will be assessed using the Katz Activities of Daily Living (ADL) Scale. Dependency in any of the following activities will be coded as 1 (dependent) versus 0 (independent): bathing, dressing, toileting, transferring from bed to chair, and feeding. Pre-admission functional status will be recorded based on patient or caregiver recall to reflect the patient's baseline prior to the acute illness.

Section D: Instrumental Activities of Daily Living - IADL (4 items):

Higher-order functional independence will be assessed using the Lawton Instrumental Activities of Daily Living (IADL) Scale. The four items assessed are: ability to use a telephone, ability to shop, ability to prepare meals, and ability to manage medications. Each item is coded as 0 (independent) or 1 (dependent).

Section E: Cognition and Mood (3 items):

Cognitive status will be evaluated using the Mini-Mental State Examination (MMSE); a score below 24 will be coded as cognitive impairment (1). Depressive symptoms will be screened using the 15-item Geriatric Depression Scale (GDS-15); a score of 6 or above will be coded as depression (1). Subjective memory complaint, defined as self-reported difficulty with memory not fully captured by formal cognitive testing, will be recorded separately and coded as 0 (absent) or 1 (present).

Section F: Physical and Laboratory Indicators (3 items):

Three objectively measured indicators will be included. Anemia is defined according to World Health Organization (WHO) criteria as a hemoglobin level below 13 g/dL in men and below 12 g/dL in women, determined from the admission complete blood count. Hypoalbuminemia is defined as a serum albumin level below 3.5 g/dL, measured using the colorimetric bromocresol green (BCG) method on the admission blood sample. Abnormal body mass index (BMI) is defined as BMI below 18.5 kg/m² (underweight) or 30 kg/m² and above (obese); body weight will be measured using a calibrated digital scale with the patient in light clothing and without footwear, and height will be measured using a wall-mounted stadiometer.

研究の種類

観察的

入学 (推定)

175

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Asma Ahmed Rafat, specialist
  • 電話番号:+201030533071
  • メール:asmaacc@yahoo.com

研究連絡先のバックアップ

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

elderly patients attending Assiut university hospital, including outpatients and inpatients who fulfill inclusion criteria.

説明

  • a. Inclusion criteria:
  • Age ≥ 60 years
  • Patient attending Assiut university hospital during the study period, regardless primary diagnosis.
  • Ability to provide informed consent and agreed to participate in the study.
  • Ability to communicate and answer the study questionnaire.
  • b. Exclusion criteria:
  • Age < 60 years
  • Patients admitted for elective surgical procedures or transferred from surgical wards
  • Patients with a terminal illness or those receiving palliative/end-of-life care only
  • Patients with incomplete medical records or inability to complete the assessment due to severe aphasia or critical hemodynamic instability
  • Patients with severe cognitive impairment or psychiatric disorders affecting communication.
  • Patients who refused to participate

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
• Patient attending Assiut university hospital during the study period aged above 60 years
  • a. Inclusion criteria:
  • Age ≥ 60 years
  • Patient attending Assiut university hospital during the study period, regardless primary diagnosis.
  • Ability to provide informed consent and agreed to participate in the study.
  • Ability to communicate and answer the study questionnaire.
  • b. Exclusion criteria:
  • Age < 60 years
  • Patients admitted for elective surgical procedures or transferred from surgical wards
  • Patients with a terminal illness or those receiving palliative/end-of-life care only
  • Patients with incomplete medical records or inability to complete the assessment due to severe aphasia or critical hemodynamic instability
  • Patients with severe cognitive impairment or psychiatric disorders affecting communication.
  • Patients who refused to participate

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
• Prevalence of frailty syndrome
時間枠:Baseline
• Prevalence of frailty syndrome among elderly patients attending Assiut university hospital, defined as FI ≥ 0.25
Baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
Socio-demographic characteristics associated with frailty syndrome
時間枠:Baseline
Assessment of age, gender, education level, living arrangement, and marital status collected via a structured questionnaire
Baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Dalia Galal Mahran, professor、Professor at Public Health and community medicine Department, Head of Family medicine department

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年7月20日

一次修了 (推定)

2027年7月20日

研究の完了 (推定)

2027年7月20日

試験登録日

最初に提出

2026年7月2日

QC基準を満たした最初の提出物

2026年7月21日

最初の投稿 (実際)

2026年7月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月27日

QC基準を満たした最後の更新が送信されました

2026年7月21日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • Frailty Syndrome

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する